PMC4751900_01
Hematoxylin and eosin staining of a tumor section (x200).
ott-9-643Fig1.jpg
PMC4751900_01_ott-9-643Fig1.jpg
f1-ott-9-643
Pathology diagnosis confirmed MFH (mostly myxofibrosarcoma, some pleomorphic forms; Figure 1) with immunophenotype: Vimentim(3+), AAT(2+), AE1/AE3(-), CD34(3+), SMA(-), Bcl2(+-), S100(-), Desmin(-), LCA(-), ALK(-), CD30(-), beta-catenin(+), CD68(+).
Chest CT images showing metastases before (A and B) and after treatment with apatinib (C, D and E, F, respectively).. Note: The arrows and arrowheads indicate the pulmonary metastases.. Abbreviation: CT, computed tomography.
ott-9-643Fig2.jpg
PMC4751900_01_ott-9-643Fig2.jpg
f2-ott-9-643
Chest CT revealed an increased metastasis in the upper lobe of right lung and a significantly increased mass of approximately 9.3 cm in diameter at the lower right parahilar (Figure 2A and B). Lung metastases were significantly reduced in size with some porosis, which was considered to be a PR (Figure 2C, D and E, F, respectively).
Main toxicities during apatinib treatment.. Notes: (A) Elevated alanine transaminase. (B) Elevated aspartate amino transferase.
ott-9-643Fig3.jpg
PMC4751900_01_ott-9-643Fig3.jpg
f3-ott-9-643
The toxicities the patient experienced were mainly non-hematological toxicities, including skin rash, short-lived elevated alanine transaminase (Figure 3A), and aspartate amino transferase (Figure 3B; grade 2; according to Common Terminology Criteria for Adverse Events v.4.03).